Type 1 DiabetesDiactive-1NCT06048757
Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1)
A study testing Diactive-1 application in people with Type 1 Diabetes, run by Fundacion Miguel Servet at 2 sites in Spain.
Trial summary
This project involves a two-arm randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a mobile application aimed at prescribing resistance training for children and adolescents with type 1 diabetes (Diactive-1). Read more about this study
- Who is it for?
- Ages 8 to 18 years
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- Diactive-1 application
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 2 sitesSpain
- Study dates
- 20 Aug 2023to 1 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Aged 8-18 years old
- At least 6 months post-diagnosis for type 1 diabetes
- Ability to complete measures and intervention program in Spanish
- Access to broadband or cellular internet
- Patients who signed the informed consent form prior to participation; for minors, a legal representative must provide consent and sign the informed consent form.
Who cannot join
- Any comorbidity limiting the capacity to participate in physical activity or inadequate understanding of the Spanish language.
- Participants will be excluded if they don't have access to the internet, lack a smartphone or tablet, or are unable to use the application.
Trial locations and contacts
2 sites in 1 country.
Spain2 sites
Fundación Miguel Servet/ Navarrabiomed
Pamplona, Navarre, 31008
Paediatric Endocrinology Unit at Hospital Universitario de Navarra
Pamplona, Navarre, 31008
About this study
Official title: Effectiveness of the Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1) on Insulin Requirements: Protocol for a Randomized Controlled Trial
This project involves a two-arm randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a mobile application aimed at prescribing resistance training for children and adolescents with type 1 diabetes (Diactive-1). The program will span 24 weeks, with a minimum weekly frequency of 3 sessions. The researchers aim to recruit 52 participants but will enroll additional participants to account for potential withdrawals and ensure compliance with the desired sample size. The primary objective of the study is to evaluate the impact of the Diactive-1 mobile application on insulin requirements in children and adolescents with Type 1 Diabetes. Additionally, the researchers will investigate the effects of the Diactive-1 program on secondary parameters such as glycemic control, cardiometabolic indicators, physical fitness, and daily physical activity, among others. The hypothesis posits that personalized training through a mobile application, primarily focusing on muscular strength, will effectively reduce the daily insulin dosage in children and adolescents with type 1 diabetes.
Read the detailed description
The primary objective of this study is to evaluate the effectiveness of the Diactive-1 mobile application, which offers personalized resistance training, in reducing daily insulin requirements among children and adolescents with type 1 diabetes.
To achieve this objective, researchers will conduct a 24 weeks randomized controlled trial involving at least 52 participants diagnosed with type 1 diabetes. The study will consist of two groups: an experimental group utilizing the Diactive-1 application and a control group receiving standard treatment. Participant allocation to either group will be determined through central randomization.
The Diactive-1 intervention encompasses several key features, including: (i) tailoring exercises based on initial physical fitness levels; (ii) adjusting the previous exercise to the glucose level measured through an interstitial glucose monitor or entered manually before the training session; (iii) monitoring heart rate during exercise; (iv) providing the flexibility to train with or without equipment, individually or with a partner; (v) dispensing diabetes management advice before and after each training session; and (vi) adapting training progressions based on session adherence. A face-to-face session will be conducted before commencing the intervention to ensure that participants are familiar with the fundamental movements, thus reducing the risk of potential muscle injuries.
- Conditions
- Type 1 Diabetes
- Being tested
- Diactive-1 application
- Keywords
- mHealth, Resistance exercise, Insulin sensitivity, Glycemic control
- Medical subject headings
- Diabetes Mellitus, Type 1, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diactive-1 applicationDevice
Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
| Study group | Role | What they receive |
|---|---|---|
| Experimental app intervention group | Experimental | The intervention in the experimental group will center around the use of a mobile application (i.e., device), namely the Diactive-1 app. Receives: Device: Diactive-1 application |
| Waiting-list control group | No intervention | This arm will not complete an intervention. Participants will be instructed to continue to follow their normal daily diabetes care plan (i.e., standard care). This group will be granted access to the app following the intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in daily insulin dose requirement
The daily insulin dose requirements will be measured in units per kilogram of body weight. Assessment will rely on participant-reported data from insulin pumps or injection logs, gathered for 9 days prior to the intervention, at 12 weeks, and after the intervention.
Measured: Baseline, 12 and 24 weeks
Secondary outcomes (42)
Change in glycated hemoglobin
Glycated hemoglobin (measured in percent)
Measured: Baseline and 24 weeks
Number of participants with good glycemic control
Number of participants with a glycated hemoglobin level lower than 7%
Measured: Baseline and 24 weeks
Change in time in range
The percentage of time a person spends with their blood glucose levels in the target range (70-180 mg/dL or 3.9-10 mmol/L) (measured in percent)
Measured: Baseline and 24 weeks
Change in time below range
The percentage of time a person spends with their blood glucose levels below the target range (<70 mg/dL or <3.9 mmol/L, i.e., hypoglycemia) (measured in percent)
Measured: Baseline and 24 weeks
Change in time above range
The percentage of time a person spends with their blood glucose levels above the target range (>180 mg/dL or 10 mmol/L, i.e., hyperglycemia) (measured in percent).
Measured: Baseline and 24 weeks
Change in glycemic variability
Glycemic variability measures the fluctuation in blood glucose levels over time, expressed as a percentage. Lower glycemic variability indicates more stable levels, while higher glycemic variability suggests greater fluctuations.
Measured: Baseline and 24 weeks
Change in compliance with 24-hour movement behaviors
Physical activity at different intensities (average min/day), sedentary time (average min/day) and sleep (average min/day) will be measured using GENEActive accelerometers and self-reported questionnaires
Measured: Baseline and 24 weeks
Change in physical activity
Physical activity will be estimated using the GENEActive triaxial accelerometer (ActivInsights) and measured in minutes per day
Measured: Baseline, 12 and 24 weeks
Change in self-reported physical activity
Aerobic and muscle-strengthening activities will be assessed using two separate ad hoc questions. Participants will have response options ranging from 0 to 7 days per week, with increments of 1 day
Measured: Baseline and 24 weeks
Change in sedentary behaviors
Sedentary behaviors will be self-reported using the Youth Leisure-Time Sedentary Behavior Questionnaire. Total daily sedentary screen time will be calculated by summing the durations of daily screen time activities. Furthermore, total screen time for both weekdays and weekends will be calculated in minutes per day
Measured: Baseline and 24 weeks
Change in sleep duration
Sleep duration will be determined by recording the number of hours slept each day in a 9-day diary
Measured: Baseline and 24 weeks
Change in sleep quality
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index questionnaire, which evaluates seven established aspects of sleep quality: subjective sleep quality, time taken to fall asleep, duration of sleep, sleep efficiency, sleep disturbances (such as nightmares, pain, or feeling too hot or cold), use of sleep medication, and daytime dysfunction. Each question is scored on a scale from 0 to 3, with higher scores indicating more pronounced sleep disturbances.
Measured: Baseline and 24 weeks
Change in blood pressure
Systolic and diastolic blood pressure will be measured in mmHg using a blood pressure monitor
Measured: Baseline and 24 weeks
Change in cardio-ankle vascular index (CAVI)
Measuring Cardio-Ankle Vascular Index (measured in percent) by VaSera VS 2000 (Fukuda Denshi, Japan)
Measured: Baseline and 24 weeks
Change in pulse wave velocity
Measuring pulse wave velocity (m/seg) by VaSera VS 2000 (Fukuda Denshi, Japan)
Measured: Baseline and 24 weeks
Change in heart rate variability
The heart rate will be recorded by a heart rate monitor in a beat-by-beat basis.
Measured: Baseline and 24 weeks
Change in disordered eating
Disordered eating will be screened using the mSCOFF questionnaire. This questionnaire consists of six straightforward yes/no questions. A positive response to two or more of these questions suggests a potential eating disorder, often requiring further evaluation.
Measured: Baseline and 24 weeks
Change in Health-Related Quality of Life in the context of a chronic illness
Health-Related Quality of Life in the context of a chronic illness will be evaluated using the Spanish version of the 'Questionnaire for Young People with Diabetes' (DISABKIDS). This questionnaire consists of 12 questions about how a patient has felt in the last four weeks, with responses rated on a 5-point Likert scale from 1 (Never) to 5 (Always)
Measured: Baseline and 24 weeks
Change in Health-Related Quality of Life
Health-Related Quality of Life will be evaluated using the Screening for and Promotion of Health-Related Quality of Life in Children and Adolescents (KIDSCREEN-10). This is a generic 10-item unidimensional instrument that assesses the functional, mental, and social aspects of well-being in children and adolescents. Each item will offer five response categories, ranging from 'never' to 'always' or from 'not at all' to 'extremely'
Measured: Baseline and 24 weeks
Change in subjective well-being
Subjective well-being will be assessed using the 'Cuestionario Unico de Bienestar Escolar' (CUBE), which comprises five items evaluating different aspects of life satisfaction. All variables will be measured on a 10-point Likert scale ranging from 0 to 10 (0 = totally disagree, 10 = totally agree).
Measured: Baseline and 24 weeks
Change in cardiorespiratory fitness
Measured with an incremental VO2 protocol on exercise bike by COSMED Quark CPET plus OMNIA (COSMED®, Rome, Italy) (measured in mL/kg/min and Metabolic Equivalents [METs])
Measured: Baseline and 24 weeks
Change in isometric strength
Handgrip strength measured in kilograms using the Takei III Smedley Type Digital Dynamometer
Measured: Baseline, 12 and 24 weeks
Change in lower limb muscle dynamic strength
Lower limb muscle strength (legs and hips) measured in kg using eGym® machines (GmbH in Munich, Germany)
Measured: Baseline and 24 weeks
Change in upper limb muscle dynamic strength
Upper limb muscle strength (chest and arms) measured in kg using eGym® machines (GmbH in Munich, Germany)
Measured: Baseline and 24 weeks
Change in lower limb muscle power strength
Lower limb muscle power (legs and hips) measured in watts using eGym® machines (GmbH in Munich, Germany)
Measured: Baseline and 24 weeks
Change in upper limb muscle power strength
Upper limb muscle power (chest and arms) measured in watts using eGym® machines (GmbH in Munich, Germany)
Measured: Baseline and 24 weeks
Change in self-reported physical fitness
The International Fitness Scale (IFIS) will be used to assess self-reported physical fitness. This scale includes five elements that will employ a 5-point Likert scale to inquire about children's overall perception of their physical fitness, as well as their perception of their cardiorespiratory fitness, muscular fitness, speed-agility, and flexibility compared to their peers. The Likert scale will provide choices ranging from 'very poor' to 'poor,' 'average,' 'good,' and 'very good' physical fitness.
Measured: Baseline and 24 weeks
Adherence to the Mediterranean Diet
For assessing adherence to the Mediterranean Diet, the KIDMED index will be employed. This index provides a score on a scale of 0 to 12, with higher scores indicating stronger adherence.
Measured: Baseline and 24 weeks
Change in dietary behavior
Self-reported food intake will be assessed using a food-frequency questionnaire (FFQ). The daily consumption of food and beverages will be categorized into 12 groups: dairy, meat, fish, eggs, vegetables, fruit, starch, legumes, nuts, sweets, soft drinks, and alcoholic drinks.
Measured: Baseline and 24 weeks
Change in body mass index
Weight and height will be combined to report body mass index in kg/m^2
Measured: Baseline, 12 and 24 weeks
Change in fat mass (percentage)
Fat mass will be measured using a dual-energy X-ray absorptiometer (DXA) and expressed as a percentage.
Measured: Baseline, 12 and 24 weeks
Change in fat mass (in kilograms)
Fat mass will be measured using a dual-energy X-ray absorptiometer (DXA) and expressed in kilograms.
Measured: Baseline, 12 and 24 weeks
Change in lean mass
Fat mass in kilograms will be measured using a dual-energy X-ray absorptiometer (DXA)
Measured: Baseline, 12 and 24 weeks
Change in subcutaneos adiposity
Subcutaneos adiposity in cm^3 will be measured using a dual-energy X-ray absorptiometer (DXA)
Measured: Baseline, 12 and 24 weeks
Change in visceral adiposity
Visceral adiposity in cm^3 will be measured using a dual-energy X-ray absorptiometer (DXA)
Measured: Baseline, 12 and 24 weeks
Change in bone mineral content
Bone mineral content in grams will be measured using a dual-energy X-ray absorptiometer (DXA)
Measured: Baseline, 12 and 24 weeks
Change in bone mineral density
Bone mineral density will be measured in grams/cm^2 using a dual-energy X-ray absorptiometer (DXA)
Measured: Baseline, 12 and 24 weeks
Change in blood lipids levels
The following parameters will be evaluated: fasting total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides, lipoprotein (a), and apolipoproteins A-I and B levels, measured in mg/dL.
Measured: Baseline and 24 weeks
Change in fasting glucose
Fasting glucose will be measured in mg/dL.
Measured: Baseline and 24 weeks
Changes in liver enzymes
The following parameters will be evaluated: alanine transaminase and aspartate aminotransferase.
Measured: Baseline and 24 weeks
Change in inadvertent hypoglycemia
The perception of hypoglycemia will be assessed using the Clarke test, which comprises eight questions with various potential answers. A score greater than 3 indicates impaired awareness of hypoglycemia.
Measured: Baseline and 24 weeks
App usability
The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS). This scale provides a comprehensive and objective measure of app usability and consists of 20 items. Each item is rated on a 5-point scale, ranging from 1 (inadequate) to 5 (excellent).
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2023
- Study start20 Aug 2023
- Primary completion1 Mar 2024
- Study completion1 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundacion Miguel Servet
- Sponsor type
- University, hospital or other
- Collaborators
- Complejo Hospitalario de Navarra, Universidad Pública de Navarra
- Responsible party
- Sponsor
- Investigators
- Antonio García-Hermoso, PhD, Principal investigator, Fundación Miguel Servet - Navarrabiomed
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06048757
- Sponsor's protocol ID
- AGH_Diactive1_2023
- Acronym
- Diactive-1
- Status last verified
- Dec 2025
- First submitted
- 28 Aug 2023
- Last updated
- 17 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Munoz-Pardeza J, Lopez-Gil JF, Hormazabal-Aguayo I, Izquierdo M, Agostinis-Sobrinho C, Ezzatvar Y, Garcia-Hermoso A. Effects of Diactive-1-Supported Progressive Resistance Training on Body Composition in Youth With Type 1 Diabetes. J Cachexia Sarcopenia Muscle. 2026 Apr;17(2):e70257. doi: 10.1002/jcsm.70257.
PubMed 41854192Hormazabal-Aguayo I, Munoz-Pardeza J, Lopez-Gil JF, Huerta-Uribe N, Chueca-Guindulain MJ, Berrade-Zubiri S, Burillo Sanchez E, Izquierdo M, Ezzatvar Y, Garcia-Hermoso A. Comprehensive management of children and adolescents with type 1 diabetes mellitus through personalized physical exercise and education using an mHealth system: The Diactive-1 study protocol. Front Endocrinol (Lausanne). 2024 Feb 6;15:1354734. doi: 10.3389/fendo.2024.1354734. eCollection 2024.
PubMed 38379866
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of the Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1) on Insulin Requirements: Protocol for a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06048757
- Acronym / sponsor ID
- Diactive-1 / AGH_Diactive1_2023
- Conditions
- Type 1 Diabetes
- Keywords
- mHealth, Resistance exercise, Insulin sensitivity, Glycemic control
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Fundacion Miguel ServetUniversity, hospital or other
- Collaborators
- Complejo Hospitalario de Navarra, Universidad Pública de Navarra
- Study start
- 20 Aug 2023 (actual)
- Primary completion
- 1 Mar 2024 (actual)
- Study completion
- 1 Oct 2024 (actual)
- First posted
- 21 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project involves a two-arm randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a mobile application aimed at prescribing resistance training for children and adolescents with type 1 diabetes (Diactive-1). The program will span 24 weeks, with a minimum weekly frequency of 3 sessions. The researchers aim to recruit 52 participants but will enroll additional participants to account for potential withdrawals and ensure compliance with the desired sample size. The primary objective of the study is to evaluate the impact of the Diactive-1 mobile application on insulin requirements in children and adolescents with Type 1 Diabetes. Additionally, the researchers will investigate the effects of the Diactive-1 program on secondary parameters such as glycemic control, cardiometabolic indicators, physical fitness, and daily physical activity, among others. The hypothesis posits that personalized training through a mobile application, primarily focusing on muscular strength, will effectively reduce the daily insulin dosage in children and adolescents with type 1 diabetes.
Detailed description
The primary objective of this study is to evaluate the effectiveness of the Diactive-1 mobile application, which offers personalized resistance training, in reducing daily insulin requirements among children and adolescents with type 1 diabetes.
To achieve this objective, researchers will conduct a 24 weeks randomized controlled trial involving at least 52 participants diagnosed with type 1 diabetes. The study will consist of two groups: an experimental group utilizing the Diactive-1 application and a control group receiving standard treatment. Participant allocation to either group will be determined through central randomization.
The Diactive-1 intervention encompasses several key features, including: (i) tailoring exercises based on initial physical fitness levels; (ii) adjusting the previous exercise to the glucose level measured through an interstitial glucose monitor or entered manually before the training session; (iii) monitoring heart rate during exercise; (iv) providing the flexibility to train with or without equipment, individually or with a partner; (v) dispensing diabetes management advice before and after each training session; and (vi) adapting training progressions based on session adherence. A face-to-face session will be conducted before commencing the intervention to ensure that participants are familiar with the fundamental movements, thus reducing the risk of potential muscle injuries.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental app intervention group | Experimental | Device: Diactive-1 applicationThe intervention in the experimental group will center around the use of a mobile application (i.e., device), namely the Diactive-1 app. |
| Waiting-list control group | No intervention | –This arm will not complete an intervention. Participants will be instructed to continue to follow their normal daily diabetes care plan (i.e., standard care). This group will be granted access to the app following the intervention. |
Who may qualify
- Ages
- 8 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Aged 8-18 years old
- At least 6 months post-diagnosis for type 1 diabetes
- Ability to complete measures and intervention program in Spanish
- Access to broadband or cellular internet
- Patients who signed the informed consent form prior to participation; for minors, a legal representative must provide consent and sign the informed consent form.
Key exclusion criteria (2 listed)
- Any comorbidity limiting the capacity to participate in physical activity or inadequate understanding of the Spanish language.
- Participants will be excluded if they don't have access to the internet, lack a smartphone or tablet, or are unable to use the application.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diactive-1 applicationParticipants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized. | Device | Experimental app intervention group |
Primary outcome
Change in daily insulin dose requirement
Time frame: Baseline, 12 and 24 weeks
The daily insulin dose requirements will be measured in units per kilogram of body weight. Assessment will rely on participant-reported data from insulin pumps or injection logs, gathered for 9 days prior to the intervention, at 12 weeks, and after the intervention.
42 secondary outcomes
Change in glycated hemoglobin
Time frame: Baseline and 24 weeks
Number of participants with good glycemic control
Time frame: Baseline and 24 weeks
Change in time in range
Time frame: Baseline and 24 weeks
Change in time below range
Time frame: Baseline and 24 weeks
Change in time above range
Time frame: Baseline and 24 weeks
Change in glycemic variability
Time frame: Baseline and 24 weeks
Change in compliance with 24-hour movement behaviors
Time frame: Baseline and 24 weeks
Change in physical activity
Time frame: Baseline, 12 and 24 weeks
Change in self-reported physical activity
Time frame: Baseline and 24 weeks
Change in sedentary behaviors
Time frame: Baseline and 24 weeks
Change in sleep duration
Time frame: Baseline and 24 weeks
Change in sleep quality
Time frame: Baseline and 24 weeks
Change in blood pressure
Time frame: Baseline and 24 weeks
Change in cardio-ankle vascular index (CAVI)
Time frame: Baseline and 24 weeks
Change in pulse wave velocity
Time frame: Baseline and 24 weeks
Change in heart rate variability
Time frame: Baseline and 24 weeks
Change in disordered eating
Time frame: Baseline and 24 weeks
Change in Health-Related Quality of Life in the context of a chronic illness
Time frame: Baseline and 24 weeks
Change in Health-Related Quality of Life
Time frame: Baseline and 24 weeks
Change in subjective well-being
Time frame: Baseline and 24 weeks
Change in cardiorespiratory fitness
Time frame: Baseline and 24 weeks
Change in isometric strength
Time frame: Baseline, 12 and 24 weeks
Change in lower limb muscle dynamic strength
Time frame: Baseline and 24 weeks
Change in upper limb muscle dynamic strength
Time frame: Baseline and 24 weeks
Change in lower limb muscle power strength
Time frame: Baseline and 24 weeks
Change in upper limb muscle power strength
Time frame: Baseline and 24 weeks
Change in self-reported physical fitness
Time frame: Baseline and 24 weeks
Adherence to the Mediterranean Diet
Time frame: Baseline and 24 weeks
Change in dietary behavior
Time frame: Baseline and 24 weeks
Change in body mass index
Time frame: Baseline, 12 and 24 weeks
Change in fat mass (percentage)
Time frame: Baseline, 12 and 24 weeks
Change in fat mass (in kilograms)
Time frame: Baseline, 12 and 24 weeks
Change in lean mass
Time frame: Baseline, 12 and 24 weeks
Change in subcutaneos adiposity
Time frame: Baseline, 12 and 24 weeks
Change in visceral adiposity
Time frame: Baseline, 12 and 24 weeks
Change in bone mineral content
Time frame: Baseline, 12 and 24 weeks
Change in bone mineral density
Time frame: Baseline, 12 and 24 weeks
Change in blood lipids levels
Time frame: Baseline and 24 weeks
Change in fasting glucose
Time frame: Baseline and 24 weeks
Changes in liver enzymes
Time frame: Baseline and 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2025.
- Derived from this study: PubMed 41854192Munoz-Pardeza J, Lopez-Gil JF, Hormazabal-Aguayo I, Izquierdo M, Agostinis-Sobrinho C, Ezzatvar Y, Garcia-Hermoso A. Effects of Diactive-1-Supported Progressive Resistance Training on Body Composition in Youth With Type 1 Diabetes. J Cachexia Sarcopenia Muscle. 2026 Apr;17(2):e70257. doi: 10.1002/jcsm.70257.
- Derived from this study: PubMed 38379866Hormazabal-Aguayo I, Munoz-Pardeza J, Lopez-Gil JF, Huerta-Uribe N, Chueca-Guindulain MJ, Berrade-Zubiri S, Burillo Sanchez E, Izquierdo M, Ezzatvar Y, Garcia-Hermoso A. Comprehensive management of children and adolescents with type 1 diabetes mellitus through personalized physical exercise and education using an mHealth system: The Diactive-1 study protocol. Front Endocrinol (Lausanne). 2024 Feb 6;15:1354734. doi: 10.3389/fendo.2024.1354734. eCollection 2024.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Type 1 Diabetes
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
A Novel Miniature Equine-Assisted Diabetes Education Program for Youth: Evaluating the Diabetes Equine Empowerment Program (DEEP).
Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antonio García-Hermoso, PhD principal investigator
Fundación Miguel Servet - Navarrabiomed
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diactive-1 application in people with Type 1 Diabetes, run by Fundacion Miguel Servet at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in daily insulin dose requirement (time frame: Baseline, 12 and 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06048757, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.